Hot Investor Mandate: Australian Family Office Invests in Early-Stage Therapeutics, Medtech, and Digital Health Companies with Clearly Established Developmental Pathways

6 Dec

A family investment vehicle based in Australia invests in early-stage life science and digital health startups. The firm is focused on the Australian and U.S. markets with directors of the fund present in both countries. The fund is flexible in terms of investment size and capital structure and may co-invest or lead financing rounds.

The firm is interested in therapeutics, medtech and digital health companies. The group has a preference for companies that have some clinical data and is most interested in indications where the science is well-understood and the development path is straight-forward. The fund is particularly interested in repurposed and orphan drugs as well as other de-risked/accelerated regulatory pathways. The firm is most interested in ophthalmology, dermatology, microbiome-related technologies, the premature infant space and orphan indications.

The firm has a strong preference for experienced management teams, and prefers companies with modest valuations and capital needs so that their investment is impactful.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: